Industry
The Human Gut Microbiome Reference Material (RM) promises to standardize and enhance research efforts in a field poised to transform healthcare.
MaaT013, a Microbiome Ecosystem Therapy™ (MET), is designed to restore the gut microbiome in pediatric patients aged 6 to 18 years with steroid-resistant aGvHD.
Positive results from Phase 1 trial of BL-001, an innovative live biotherapeutic product (LBP) designed to replicate the metabolic effects of the ketogenic diet.
The approval is major step forward in the fight against recurrent C. diff infection.
Financing will also support analysis of real-world evidence in people with CF to explore the relationship between P. aeruginosa reduction and clinical outcomes.
Seres Therapeutics, a leader in the live biotherapeutics space, has received pivotal feedback from the U.S. Food and Drug Administration (FDA) regarding the development of its lead investigational treatment, SER-155,…
Industry
Sponsored by
In July 2024, the journal Frontiers in Microbiology presented a groundbreaking method that overcomes this hurdle: the Flow-FISH method.
Industry
Sponsored by
Probiotic intervention in the gut–prostate axis with novaPROX combo: insights from an in vitro study
The study published on Foods Journal researched the mechanisms of action of Probionova's novaPROX product using a 3D intestinal barrier model and a co-culture prostatic model.
On the second anniversary of its launch, Ferring Pharmaceuticals’ REBYOTA remains a landmark innovation in the prevention of recurrent Clostridioides difficile.
Lonza's capsules ensures targeted intestinal delivery enhancing stability and therapeutic efficacy for LBPs and pharmaceutical applications.
